Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
Research output: Contribution to journal › Journal article › Research › peer-review
BACKGROUND: Weight-loss drugs produce an additional mean weight loss of only 3-5 kg above that of diet and placebo over 6 months, and more effective pharmacotherapy of obesity is needed. We assessed the efficacy and safety of tesofensine-an inhibitor of the presynaptic uptake of noradrenaline, dopamine, and serotonin-in patients with obesity. METHODS: We undertook a phase II, randomised, double-blind, placebo-controlled trial in five Danish obesity management centres. After a 2 week run-in phase, 203 obese patients (body-mass index 30-
Original language | English |
---|---|
Journal | Lancet |
Volume | 372 |
Issue number | 9653 |
Pages (from-to) | 1906-13 |
Number of pages | 7 |
DOIs | |
Publication status | Published - 2008 |
ID: 34068914